Case reports: efalizumab-associated lymphoproliferative disease.

Satya Bommakanti, Amol Patil, Camellia Eshoa, Christopher R. Chitambar

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Efalizumab is an immunosuppressive agent that has been approved for the treatment of psoriasis. There has been mounting evidence that efalizumab may be associated with lymphoma/malignancy development. To our knowledge, this is the first documented case of a patient who developed Epstein Barr Virus-associated large B cell lymphoma after treatment with efalizumab for psoriasis. As immunosuppressive medications such as efalizumab get increasingly prescribed, the likelihood of seeing various malignancies will increase. Thus, physicians need to have a high index of suspicion for malignancy in patients on immunosuppressive medications like efalizumab.

Original languageEnglish (US)
Pages (from-to)646-648
Number of pages3
JournalJournal of drugs in dermatology : JDD
Volume6
Issue number6
StatePublished - Jun 2007

Fingerprint

Immunosuppressive Agents
Psoriasis
Neoplasms
B-Cell Lymphoma
Human Herpesvirus 4
Lymphoma
efalizumab
Physicians
Therapeutics

ASJC Scopus subject areas

  • Dermatology

Cite this

Case reports : efalizumab-associated lymphoproliferative disease. / Bommakanti, Satya; Patil, Amol; Eshoa, Camellia; Chitambar, Christopher R.

In: Journal of drugs in dermatology : JDD, Vol. 6, No. 6, 06.2007, p. 646-648.

Research output: Contribution to journalArticle

Bommakanti, S, Patil, A, Eshoa, C & Chitambar, CR 2007, 'Case reports: efalizumab-associated lymphoproliferative disease.', Journal of drugs in dermatology : JDD, vol. 6, no. 6, pp. 646-648.
Bommakanti, Satya ; Patil, Amol ; Eshoa, Camellia ; Chitambar, Christopher R. / Case reports : efalizumab-associated lymphoproliferative disease. In: Journal of drugs in dermatology : JDD. 2007 ; Vol. 6, No. 6. pp. 646-648.
@article{560b7a786c574cb6993f5ddda68c0ac3,
title = "Case reports: efalizumab-associated lymphoproliferative disease.",
abstract = "Efalizumab is an immunosuppressive agent that has been approved for the treatment of psoriasis. There has been mounting evidence that efalizumab may be associated with lymphoma/malignancy development. To our knowledge, this is the first documented case of a patient who developed Epstein Barr Virus-associated large B cell lymphoma after treatment with efalizumab for psoriasis. As immunosuppressive medications such as efalizumab get increasingly prescribed, the likelihood of seeing various malignancies will increase. Thus, physicians need to have a high index of suspicion for malignancy in patients on immunosuppressive medications like efalizumab.",
author = "Satya Bommakanti and Amol Patil and Camellia Eshoa and Chitambar, {Christopher R.}",
year = "2007",
month = "6",
language = "English (US)",
volume = "6",
pages = "646--648",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "6",

}

TY - JOUR

T1 - Case reports

T2 - efalizumab-associated lymphoproliferative disease.

AU - Bommakanti, Satya

AU - Patil, Amol

AU - Eshoa, Camellia

AU - Chitambar, Christopher R.

PY - 2007/6

Y1 - 2007/6

N2 - Efalizumab is an immunosuppressive agent that has been approved for the treatment of psoriasis. There has been mounting evidence that efalizumab may be associated with lymphoma/malignancy development. To our knowledge, this is the first documented case of a patient who developed Epstein Barr Virus-associated large B cell lymphoma after treatment with efalizumab for psoriasis. As immunosuppressive medications such as efalizumab get increasingly prescribed, the likelihood of seeing various malignancies will increase. Thus, physicians need to have a high index of suspicion for malignancy in patients on immunosuppressive medications like efalizumab.

AB - Efalizumab is an immunosuppressive agent that has been approved for the treatment of psoriasis. There has been mounting evidence that efalizumab may be associated with lymphoma/malignancy development. To our knowledge, this is the first documented case of a patient who developed Epstein Barr Virus-associated large B cell lymphoma after treatment with efalizumab for psoriasis. As immunosuppressive medications such as efalizumab get increasingly prescribed, the likelihood of seeing various malignancies will increase. Thus, physicians need to have a high index of suspicion for malignancy in patients on immunosuppressive medications like efalizumab.

UR - http://www.scopus.com/inward/record.url?scp=34548462490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548462490&partnerID=8YFLogxK

M3 - Article

C2 - 17668531

AN - SCOPUS:34548462490

VL - 6

SP - 646

EP - 648

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 6

ER -